For example, the ability of GZ17-6.02 to reduce the expression of HDACs1/2/3 was enhanced in the MM cells compared to solid tumor cells whereas the degradation of HDAC6 was reduced. This evidence concerns the gene HDAC6 and Miyoshi myopathy.